Iovance Biotherapeutics, Inc. (IOVA) Stock Score, Valuation & Financial Research
Iovance Biotherapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 33/100.
Quick answer for IOVA
Iovance Biotherapeutics, Inc. currently has a Wall Street Score of 33/100. The stored market price is $8.6. Its financial score is 50/100. Its valuation score is 0/100. The latest WSS change is +0.4 points. These figures are a research snapshot, not a buy or sell recommendation.
What Iovance Biotherapeutics, Inc. does
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguis
IOVA financial snapshot
- Wall Street Score:
- 33/100
- Current price:
- $8.6
- Market capitalization:
- $3.84B
- Revenue:
- $325.0M
- Net income:
- $-289.5M
- Free cash flow:
- $-336.2M
- Cash:
- $110.8M
- Total debt:
- $46.0M
- EPS:
- -1.09
- Financial score:
- 50/100
- Valuation score:
- 0/100
- Revenue score:
- 39/100
What stands out
- Reported year-over-year revenue growth is +0.2%.
- Free cash flow is $-336.2M, showing cash burn in the current stored period.
- The balance sheet shows $110.8M of cash versus $46.0M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.4 points: IOVA increased 0.4 points because Revenue improved by 9 points.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 50/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research IOVA
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.